Researchers from Cincinnati Children’s Hospital Medical Center and collaborating institutions in the U.S. have developed a novel approach using allergen-encoding mRNA encapsulated in lipid nanoparticles (LNPs) for both therapy and prevention of allergic responses.

Familial dysautonomia (FD) is an autosomal recessive neurodevelopmental disorder.

Cyclana Bio Ltd. has closed a £5 million (US$6.7 million) pre-seed funding round.

A year and half from its inception, Adcytherix SAS has raised a €105 million (US$122 million) series A, enabling it to take the lead antibody-drug conjugate (ADC) program into clinical development next year.